A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
Phase of Trial: Phase II/III
Latest Information Update: 19 Jan 2019
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Dec 2018 Planned End Date changed from 25 Dec 2021 to 29 Aug 2022.
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.
- 08 Mar 2018 Planned End Date changed from 23 Jul 2021 to 25 Dec 2021.